[¹⁸F]FDG-PET/CT radiomics and artificial intelligence in lung cancer: Technical aspects and potential clinical applications

Lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide. Molecular imaging using [¹⁸F]fluorodeoxyglucose Positron Emission Tomography and/or Computed Tomography ([¹⁸F]FDG-PET/CT) plays an essential role in the diagnosis, evaluation of response to treatment, and prediction of outcomes. The images are evaluated using qualitative and conventional quantitative indices. However, there is far more information embedded in the images, which can be extracted by sophisticated algorithms. Recently, the concept of uncovering and analyzing the invisible data extracted from medical images, called radiomics, is gaining more attention. Currently, [¹⁸F]FDG-PET/CT radiomics is growingly evaluated in lung cancer to discover if it enhances the diagnostic performance or implication of [¹⁸F]FDG-PET/CT in the management of lung cancer. In this review, we provide a short overview of the technical aspects, as they are discussed in different articles of this special issue. We mainly focus on the diagnostic performance of the [¹⁸F]FDG-PET/CT‐based radiomics and the role of artificial intelligence in non-small cell lung cancer, impacting the early detection, staging, prediction of tumor subtypes, biomarkers, and patient's outcomes.